The work sheds light on a mysterious class of receptors known as “class B” G protein-coupled receptors (GPCRs).
The agreement, which marks first partnership of its kind between a research institution and reagents company, is the third major deal in TSRI’s new partnering strategy.
The compound, developed by the Burris lab, could lead to new help for people with exercise-limiting conditions, such as obesity, chronic obstructive pulmonary disease and congestive heart failure.
The study from the Reed lab sheds light on an enzyme known as parkin, whose absence causes an early-onset form of Parkinson’s disease.
Donated computing power on Android phones can help model evolving mutations in HIV.